Pharmacy - Emergency Medicine Deep Dive Podcast delivers high-impact, high-yield clinical pearls in emergency medicine, with a focus on pharmacotherapy and EM critical care. Each episode explores real-world cases, unpacks emerging research, and breaks down the latest evidence to support confident, informed decisions at the bedside. Notebook LM AI cuts down the time spent on manual scripting and narration, making episode production more efficient while maintaining clinical insight and timely, practical knowledge. If you’re into meds, mechanisms, and critical decision-making, this is for you!
When a cardiac arrest or trauma activation is called, most people think of physicians, nurses, and respiratory therapists. But what role does the emergency medicine pharmacist play when every second counts? In this episode, we explore the growing evidence behind pharmacists on resuscitation teams, from improving ACLS guideline adherence and reducing medication errors to helping deliver life-saving therapies more quickly. We also discuss what happens behind the scenes during a Code Blue, the specialized training that prepares pharmacists for these high-stakes situations, and the challenges that continue to limit their integration into emergency departments. Whether you're an emergency clinician, pharmacist, learner, or simply curious about how resuscitation teams work, this episode offers an evidence-based look at why pharmacists are becoming an increasingly important part of emergency care. As an emergency medicine pharmacist, this is a topic that is especially meaningful to me and I'm excited to share both the evidence and the real-world perspective behind it.
Restarting blood thinners after an intracranial hemorrhage is one of the most challenging decisions in neurology and stroke care. Restart too early and the risk of recurrent bleeding rises. Wait too long and patients may be left vulnerable to stroke or other thromboembolic complications. In this episode, we break down the latest evidence on when to resume antiplatelet and anticoagulant therapy, why recommendations differ for conditions such as mechanical heart valves and atrial fibrillation, and how factors like hemorrhage location and cerebral amyloid angiopathy shape decision making. We also explore how imaging findings and validated risk assessment tools can help individualize treatment for each patient. Whether you're a neurologist, emergency physician, internist, pharmacist, or trainee, you'll leave with practical, evidence-based strategies to navigate one of the most complex dilemmas in modern neurovascular care.
Your patient has a pulse again, but will your vasopressor choice determine whether they keep it? In this episode, we tackle one of the most common yet underappreciated decisions in post-cardiac arrest care: epinephrine or norepinephrine for post-ROSC hypotension. We break down the physiology of the stunned myocardium, explore why epinephrine may increase the risk of recurrent cardiac arrest, and examine the landmark trials and latest meta-analysis that are reshaping clinical practice. Most importantly, we translate the evidence into practical bedside recommendations you can apply on your very next shift. If you care for critically ill patients in the emergency department, ICU, or anywhere along the resuscitation continuum, this is an episode you won't want to miss.
Sepsis demands timely, effective antimicrobial therapy, but does how we administer beta-lactam antibiotics matter? In this episode, we take a deeper dive into the growing evidence behind prolonged beta-lactam infusion strategies and explore why recent guidelines now recommend extended or continuous infusions for many patients with sepsis and septic shock. We unpack the pharmacokinetic and pharmacodynamic principles, review key clinical trials and meta-analyses demonstrating improved outcomes, and discuss the critical role of an appropriate loading dose. We also examine which patient populations may benefit the most, including those with augmented renal clearance or altered physiology and when therapeutic drug monitoring should be considered. Finally, we tackle the practical challenges of implementing prolonged infusions in clinical practice, from drug stability and IV compatibility to the unanswered questions surrounding antimicrobial resistance.
Ketamine is best known for its roles in analgesia, sedation, and depression, but could it also help patients navigate the most challenging phase of opioid agonist therapy initiation in the fentanyl era? In this episode, we explore the emerging science behind ketamine as an adjunctive treatment for opioid withdrawal and OAT initiation, including its potential effects on NMDA receptors, opioid tolerance, and receptor signaling. We review the latest clinical evidence, from case reports of refractory withdrawal to early studies suggesting improved retention in treatment through rapid relief of depression and withdrawal distress. We'll also unpack the fascinating biology of beta-arrestin, receptor internalization, and whether ketamine may help improve opioid responsiveness by rebalancing some of the neurobiological changes associated with chronic fentanyl exposure. Join us as we separate promise from proof and discuss where ketamine may fit and where it may not in the future of addiction care.
In this episode, we explore the race against time in trauma care and why every minute matters when treating life-threatening bleeding. Drawing on evidence from major clinical trials and meta-analyses, we examine how tranexamic acid (TXA) can dramatically improve survival when administered as early as possible after injury. You'll learn why the greatest benefits occur within the first hour, why effectiveness begins to decline after 90 minutes, and how even short delays can significantly reduce a patient's chance of survival. We also discuss emerging evidence suggesting that rapid treatment may be more important than where the treatment is delivered. Whether you're a healthcare professional, student, or simply interested in emergency medicine, this episode highlights how timely intervention can save lives in trauma, hemorrhagic shock, and traumatic brain injury.
How low should you go when lowering blood pressure in acute intracerebral hemorrhage, and can treating too aggressively actually cause harm? In this episode, we explore the pathophysiology of ICH, including why spontaneous hemorrhage lacks a true ischemic penumbra and how perihematomal benign oligemia supports the safety of blood pressure reduction. We review the landmark INTERACT-2 and ATACH-II trials, along with the newer INTERACT-3 and INTERACT-4 studies, to uncover how the evidence has shaped modern practice and reinforced the lesson that lower is not always better. We discuss current guideline recommendations, including the shift toward a systolic blood pressure target of 130 to 150 mmHg and the importance of minimizing blood pressure variability. Finally, we compare commonly used agents such as nicardipine and clevidipine and revisit the longstanding controversy surrounding hydralazine and its purported effects on intracranial pressure and hematoma expansion.
In toxicology-induced status epilepticus, the clock starts ticking the moment first-line benzodiazepines fail. In this episode, we dive into the evolving evidence behind second-line therapies for benzodiazepine-refractory seizures, exploring why phenobarbital remains the best-supported option based on pharmacologic principles and animal data, while propofol emerges as a powerful rescue therapy in intubated patients. We also unpack the growing interest in levetiracetam, a medication praised for its favorable safety profile and minimal cardiorespiratory effects, but whose effectiveness in toxicologic seizures remains uncertain, particularly in stimulant-related cases highlighted by the ESETT subgroup analysis. Along the way, we examine why older agents like phenytoin may have little to no role in poisoned patients despite their historic use in seizure management. Through real-world clinical dilemmas, pharmacology insights, and emerging research, we explore how emergency clinicians navigate the race to stop seizures before irreversible neurological injury occurs. Whether you’re passionate about emergency medicine, toxicology, critical care, or neuropharmacology, this episode delivers a fascinating look at one of medicine’s highest-stakes treatment decisions.
Stroke thrombolysis is rapidly evolving and tenecteplase is emerging as one of the most exciting developments in acute ischemic stroke care. In this episode, we explore how a simple change from a one-hour infusion to a single IV bolus could transform stroke treatment workflows, improve transfer logistics, and potentially enhance early reperfusion in some patients. We unpack the science behind tenecteplase, review the landmark trials that challenged alteplase’s decades-long dominance, and discuss why clinicians around the world are paying close attention. From breakthrough studies in large vessel occlusion to major safety and non-inferiority trials, this episode highlights the evidence shaping modern stroke practice. This episode offers a practical and engaging overview of one of the biggest shifts in contemporary stroke care.
In this episode, we dive into the evolving evidence behind proton pump inhibitors (PPIs) in the management of nonvariceal upper gastrointestinal bleeding. While PPIs have long been considered standard early therapy, emerging data challenge whether starting treatment before endoscopy meaningfully improves major clinical outcomes such as mortality, surgery, or overall rebleeding rates. We explore how current evidence suggests the clearest benefit may be in patients with confirmed peptic ulcer bleeding, where PPIs can help reduce recurrent bleeding after endoscopic therapy. The episode also examines the growing shift away from continuous IV infusions toward intermittent dosing strategies, which appear similarly effective while potentially reducing cost and resource use. Join us as we unpack how evidence-based medicine is reshaping long-standing practices in emergency gastrointestinal care.
Ondansetron is a widely used antiemetic, but concerns have long circulated about its potential to prolong the QT interval and trigger dangerous arrhythmias like torsades de pointes. In this episode, we explore what the evidence actually shows, drawing on large-scale research including a review of over 32,000 surgical patients and a meta-analysis of 170 clinical trials. The data consistently suggests that at standard low doses, the risk of serious cardiac events is extremely low for most patients. We also unpack why reported adverse outcomes are often linked to underlying heart conditions rather than the medication itself, and how administration strategies like slower IV delivery or oral dosing may further reduce risk. Finally, we examine whether routine ECG monitoring is truly necessary in low-risk patients and what this means for everyday clinical practice.
In this episode, we unpack the long-standing controversy around combining IM olanzapine with benzodiazepines like lorazepam in the management of acute agitation. While warnings from regulators such as the U.S. Food and Drug Administration have historically discouraged this pairing due to concerns about respiratory depression, we take a closer look at the data behind those risks. Emerging evidence suggests that adverse outcomes may be less common than previously feared, especially when doses are spaced appropriately and polypharmacy is minimized. We explore how this evolving literature challenges rigid institutional practices and what it means for bedside decision making in the ED. Tune in for a practical, evidence based approach to balancing safety and effectiveness in agitation management.
In this episode, we break down the landmark CAPE COD trial and what it means for treating severe community-acquired pneumonia. Discover how early hydrocortisone use can significantly reduce mortality and the need for mechanical ventilation in critically ill patients, and why that is reshaping clinical practice. We also explore contrasting evidence from other studies, fueling an ongoing debate about when steroids truly make a difference. From patient selection to risks like hyperglycemia, we unpack the nuance behind the headlines. Tune in to understand where the evidence stands and how it is changing the way clinicians approach severe pneumonia.
What if a simple shift in how we use fluids and diuretics could transform outcomes in acute heart failure? In this episode, we explore the emerging strategy of combining hypertonic saline with high dose furosemide and why it is gaining attention in acute decompensated heart failure care. We break down how this approach can enhance fluid removal, improve kidney function, and even reduce mortality and hospital length of stay. You will also learn why this therapy may be especially valuable for patients with diuretic resistance, kidney dysfunction, or low sodium levels. We unpack the physiology behind improved renal blood flow and reduced harmful hormonal activation, while addressing common safety concerns. Finally, we examine the limitations of current evidence and what still needs to be answered before this strategy becomes mainstream.
Sepsis care is entering a new era, as the 2026 CCM Surviving Sepsis Guidelines shift practice away from “throw everything at it” toward precision pharmacotherapy, giving the right drugs at the right dose and stopping unnecessary ones early. In this episode, we break down the strongest recommendations, from extended-infusion β-lactams that optimize antibiotic exposure to permissive hypotension strategies in older adults that reduce vasopressor use. We also explore the end of the “vitamin era,” with IV Vitamin C and D no longer recommended, and where corticosteroids still play a conditional role in septic shock. Fluid therapy guidance now favors balanced crystalloids to protect kidney function, while aggressive antimicrobial stewardship emphasizes de-escalation and avoiding routine empiric coverage. Tune in to understand how these landmark updates are reshaping critical care practice and making sepsis treatment smarter, safer, and more precise.
Choosing the right DOAC is not just about preventing clots, it is about maximizing safety for every patient. In this episode, we unpack the latest evidence on direct oral anticoagulants, including the practice changing COBRRA trial comparing apixaban and rivaroxaban. Discover why similar effectiveness can come with very different bleeding risks, and how that should shape your prescribing decisions. We also explore high yield clinical pearls, from taking rivaroxaban with food to renal dosing and the unique properties of each DOAC. Whether you are in practice or still learning, this episode will help you confidently navigate DOAC selection in real world care.
What happens to antibiotics when the body is in crisis? In this episode, we dive into the fascinating and often unpredictable pharmacokinetic changes that occur in critically ill patients and why these shifts make precise antibiotic dosing essential. We explore how conditions such as sepsis and aggressive fluid resuscitation can dramatically alter drug distribution and clearance, especially for hydrophilic medications compared with their lipophilic counterparts. Along the way, we unpack key concepts like half life, steady state, and the role of loading doses in reaching therapeutic targets quickly. We also break down the difference between time dependent and concentration dependent antibiotic strategies and how these principles guide real world dosing decisions. Join us as we translate complex pharmacology into practical insights for navigating the high stakes environment of critical care medicine.
When a patient arrives in the emergency department in a state of extreme agitation or excited delirium, every second counts. In this episode, we explore the growing use of ketamine as a rapid intervention to control dangerous psychomotor agitation when traditional sedatives may act too slowly. Research shows ketamine can achieve adequate sedation far faster than medications like haloperidol, lorazepam, or midazolam, helping protect both patients and medical teams in high risk situations. But speed comes with tradeoffs, including a higher risk of complications such as hypoxia and the possible need for airway support. We unpack what the literature says about when ketamine may be appropriate and why careful cardiopulmonary monitoring is essential. Join us as we examine how clinicians balance urgency, safety, and evidence when managing one of the most challenging emergencies in acute care.
In this episode, we unpack the 2025 ACLS medication updates from the American Heart Association and what they mean for real-world cardiac arrest care. Epinephrine remains the standard for improving short-term survival, but evidence is still limited when it comes to long-term neurological outcomes. Alternative vasopressors and high-dose strategies show no clear advantage and routine use of calcium, sodium bicarbonate, and magnesium is not recommended. We also explore the nuanced role of amiodarone and lidocaine in select shockable arrests. Above all, the guidelines reinforce what saves lives most: rapid defibrillation, high-quality CPR, and getting the basics right.
The fever persists but does that mean treatment is failing? Not necessarily. In this episode we unpack why ongoing fevers do not automatically signal the need to escalate antibiotics. Instead, smart stewardship focuses on the bigger picture including hemodynamic stability, improving organ function, and microbiologic data that reveal the true course of infection. You will learn how to interpret persistent fevers, avoid unnecessary drug toxicity, and make informed decisions that fight antibiotic resistance all without overreacting to the thermometer.
